• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

    5/20/25 4:34:34 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GARRETT SCOTT T

    (Last) (First) (Middle)
    C/O HCW BIOLOGICS INC
    2929 N. COMMERCE PARKWAY

    (Street)
    MIRAMAR FL 33025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HCW Biologics Inc. [ HCWB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/16/2025 P 13,423(1) A $7.45 25,505 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These shares were issued pursuant to a conversion of Unsecured Convertible Promissory Notes which were issued to six holders through a Company financing of an aggregate principal of $270,000 in one-year Notes. The Notes contained a mandatory conversion provision, which resulted in the Notes converting into shares of common stock at a mandatory conversion price of $7.45 per share as set by the registered offering. The Notes converted after the closing of the Company's registered offering on May 15, 2025. The conversion transaction also included an allocated portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company.
    /s/ Nicole Valdivieso, as Attorney-in-Fact for Scott T. Garrett 05/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HCWB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

      MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a difficult market without

      5/15/25 6:14:42 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

      MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced the pricing of its follow-on offering of an aggregate of 671,140 units at a purchase price of $7.45 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock (or pre-funded warrant in lieu thereof) and two warrants, each to purchase one share of common stock. The warrants will have an exercise price of $7.45 per share, will be exercisable immed

      5/13/25 8:01:40 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

      Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association of Immunologists MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ("HCWB" or the "Company") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor - T

      5/13/25 8:30:20 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on HCW Biologics with a new price target

      EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

      11/19/21 8:39:08 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Financials

    Live finance-specific insights

    See more
    • HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

      MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2022. "We have achieved several milestones in the first half of 2022, and some important pieces of our strategic plan have fallen into place. First, we are now a clinical-stage company, with the entry of our lead product candidate, HCW9218, into the clinic in a

      8/12/22 7:00:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights

      MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022. "We continue to successfully execute our clinical development strategy which is based on our unique approach toward inflammaging," stated Hing C. Wong, Founder and CEO of HCW Biologics Inc. "HCW Biologics is developing immunotherapeutics that do not treat a single indica

      5/13/22 7:15:00 AM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

      SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

      11/22/24 4:53:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Wong Hing C bought $60,002 worth of shares (8,054 units at $7.45), increasing direct ownership by 2% to 501,911 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:35 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Winer Gary M bought $9,998 worth of shares (1,342 units at $7.45), increasing direct ownership by 49% to 4,075 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:35:07 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Garrett Scott T bought $100,001 worth of shares (13,423 units at $7.45), increasing direct ownership by 111% to 25,505 units (SEC Form 4)

      4 - HCW Biologics Inc. (0001828673) (Issuer)

      5/20/25 4:34:34 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    SEC Filings

    See more
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      5/30/25 4:30:17 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      5/23/25 4:30:12 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HCW Biologics Inc. filed SEC Form 8-K: Other Events

      8-K - HCW Biologics Inc. (0001828673) (Filer)

      5/20/25 4:30:15 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    See more
    • HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

      MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

      4/1/24 4:10:32 PM ET
      $HCWB
      Biotechnology: Pharmaceutical Preparations
      Health Care